Proficio Capital Partners LLC bought a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The fund bought 150,906 shares of the company's stock, valued at approximately $62,391,000. IDEXX Laboratories accounts for 0.8% of Proficio Capital Partners LLC's investment portfolio, making the stock its 14th largest holding. Proficio Capital Partners LLC owned about 0.18% of IDEXX Laboratories at the end of the most recent reporting period.
A number of other hedge funds also recently made changes to their positions in the business. FSA Wealth Management LLC bought a new stake in IDEXX Laboratories in the 3rd quarter valued at about $25,000. Ashton Thomas Securities LLC bought a new stake in IDEXX Laboratories in the 3rd quarter valued at about $37,000. Retirement Wealth Solutions LLC bought a new stake in IDEXX Laboratories in the 4th quarter valued at about $31,000. Kestra Investment Management LLC bought a new stake in IDEXX Laboratories in the 4th quarter valued at about $38,000. Finally, Crews Bank & Trust bought a new stake in IDEXX Laboratories in the 4th quarter valued at about $41,000. 87.84% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets
A number of brokerages recently issued reports on IDXX. Piper Sandler boosted their price objective on IDEXX Laboratories from $435.00 to $510.00 and gave the company a "neutral" rating in a research note on Monday, February 10th. Leerink Partnrs upgraded IDEXX Laboratories to a "strong-buy" rating in a research report on Monday, December 2nd. StockNews.com cut IDEXX Laboratories from a "buy" rating to a "hold" rating in a research report on Friday, March 7th. Barclays upped their price target on IDEXX Laboratories from $481.00 to $520.00 and gave the company an "overweight" rating in a research report on Tuesday, February 4th. Finally, Morgan Stanley decreased their price target on IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating on the stock in a research report on Wednesday, January 29th. Four research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $533.75.
Get Our Latest Research Report on IDXX
IDEXX Laboratories Stock Down 1.5 %
Shares of NASDAQ IDXX opened at $406.29 on Friday. IDEXX Laboratories, Inc. has a 12 month low of $398.50 and a 12 month high of $548.88. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28. The firm has a market capitalization of $33.04 billion, a price-to-earnings ratio of 38.08, a PEG ratio of 3.41 and a beta of 1.39. The business has a 50-day moving average of $438.04 and a 200-day moving average of $447.73.
Insider Transactions at IDEXX Laboratories
In other IDEXX Laboratories news, EVP George Fennell sold 9,986 shares of the company's stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $462.53, for a total value of $4,618,824.58. Following the completion of the sale, the executive vice president now owns 8,176 shares of the company's stock, valued at $3,781,645.28. This represents a 54.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director M Anne Szostak sold 3,000 shares of the company's stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $465.94, for a total value of $1,397,820.00. Following the completion of the sale, the director now directly owns 3,061 shares of the company's stock, valued at approximately $1,426,242.34. This represents a 49.50 % decrease in their position. The disclosure for this sale can be found here. 2.18% of the stock is owned by insiders.
IDEXX Laboratories Company Profile
(
Free Report)
IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.
See Also
Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider IDEXX Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IDEXX Laboratories wasn't on the list.
While IDEXX Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
